全文获取类型
收费全文 | 3827篇 |
免费 | 459篇 |
国内免费 | 129篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 39篇 |
口腔科学 | 4篇 |
临床医学 | 86篇 |
内科学 | 106篇 |
皮肤病学 | 19篇 |
神经病学 | 6篇 |
特种医学 | 21篇 |
外国民族医学 | 1篇 |
外科学 | 77篇 |
综合类 | 1041篇 |
现状与发展 | 1篇 |
预防医学 | 43篇 |
眼科学 | 10篇 |
药学 | 386篇 |
4篇 | |
中国医学 | 2540篇 |
肿瘤学 | 21篇 |
出版年
2024年 | 18篇 |
2023年 | 70篇 |
2022年 | 133篇 |
2021年 | 193篇 |
2020年 | 215篇 |
2019年 | 168篇 |
2018年 | 164篇 |
2017年 | 239篇 |
2016年 | 262篇 |
2015年 | 200篇 |
2014年 | 367篇 |
2013年 | 249篇 |
2012年 | 301篇 |
2011年 | 335篇 |
2010年 | 261篇 |
2009年 | 151篇 |
2008年 | 94篇 |
2007年 | 122篇 |
2006年 | 141篇 |
2005年 | 76篇 |
2004年 | 101篇 |
2003年 | 84篇 |
2002年 | 74篇 |
2001年 | 66篇 |
2000年 | 72篇 |
1999年 | 39篇 |
1998年 | 42篇 |
1997年 | 31篇 |
1996年 | 24篇 |
1995年 | 25篇 |
1994年 | 23篇 |
1993年 | 24篇 |
1992年 | 18篇 |
1991年 | 13篇 |
1990年 | 6篇 |
1989年 | 7篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有4415条查询结果,搜索用时 62 毫秒
91.
Background:Myasthenia gravis is a common autoimmune disease in clinic. Although there are various ways and drugs for the treatment of myasthenia gravis in Western medicine, there are still a variety of adverse reactions. Studies have shown that Buzhong Yiqi decoction combined with Western medicine has a certain efficacy in the treatment of myasthenia gravis, but there is a lack of evidence-based medicine. The research carried out in this scheme is to systematically evaluate the efficacy and safety of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis, and to provide reliable evidence for guiding clinical practice.Methods:English databases (the Cochrane Library, PubMed, Web of Science, Embase) and Chinese databases (China Biomedical Database, China Science and Technology Journal Database, China National Knowledge Infrastructure, Wanfang) will be searched by computer. In addition, Baidu Academic and Chinese Clinical Trial Registration Center will be searched manually. A randomized controlled clinical trial of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis will be conducted from the establishment of the database to December 2020. The 2 researchers independently carry out data extraction and literature quality evaluation on the quality of the included study, and meta-analysis of the included literature will be carried out by using RevMan 5.3 software.Results:This study will evaluate the efficacy and safety of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis by Quantitive MGscore, the number of Tregs cells and the content of anti-acetylcholine receptor antibody (AchR-Ab).Conclusion:This study will provide reliable evidence-based evidence for the clinical application of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis.Ethics and dissemination:Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences.OSF Registration number:DOI 10.17605/OSF.IO/MXUPK. 相似文献
92.
目的:研究青银汤的解热、镇痛作用.方法:通过干酵母所致大鼠发热实验观察其解热作用,通过热板法和醋酸扭体法观察其镇痛作用.结果:解热实验显示,青银汤中、高剂量组能显著抑制酵母诱导大鼠致热反应;镇痛实验显示,青银汤中、高剂量组能提高小鼠的痛阈值,有效地减少醋酸所致小鼠的扭体次数.结论:青银汤具有良好解热、镇痛作用. 相似文献
93.
【目的】探讨益气活血片对人工寒潮促发脑卒中大鼠凝血和纤溶系统的影响。【方法】选用SD大鼠,随机分为4组,按照双肾双夹法复制易卒中型肾血管性高血压大鼠模型,中药组给予益气活血片(剂量为1.89 g·kg-1·d-1),阳性对照组给予阿司匹林(剂量为80 mg·kg-1·d-1),模型组及空白对照组给予等容积蒸馏水,从高血压模型复制术后14 d开始,每天1次,直到112 d后置于人工寒潮箱中3 d诱发卒中,取血检测血浆凝血酶激活的纤溶抑制物(TAFI)、蛋白C (PC)、凝血酶—抗凝血酶复合物(TAT)及纤溶酶(PAP)水平。【结果】与模型组比较,益气活血片组可显著降低血浆TAFI、 PC、 TAT、 PAP水平,差异均有统计学意义(P<0.05)。【结论】益气活血片对脑卒中的防治作用与其能改善凝血和纤溶系统的平衡状态有关。 相似文献
94.
【目的】探讨益气活血通络法治疗冠心病的疗效以及对血管内皮功能、免疫调节的影响。【方法】将82例冠心病患者随机分为治疗组和对照组各41例,对照组给予常规西药治疗,治疗组在对照组基础上加服益气活血通络方,比较2组心绞痛疗效、心电图疗效和临床症状疗效,观察2组治疗前后血浆血管内皮生长因子(VEGF)、内皮素-1(ET-1)及超敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)等指标的变化情况。【结果】(1)治疗后,2组心绞痛疗效及心电图疗效比较,差异无统计学意义(P>0.05);临床症状疗效方面,治疗组优于对照组(P<0.05)。(2)治疗后,治疗组VEGF含量显著升高,ET-1含量显著下降(P<0.01);对照组治疗前后VEGF、ET-1含量比较,差异均无统计学意义(P>0.05);治疗组在改善VEGF、ET-1含量方面均显著优于对照组(P<0.01)。(3)治疗后,治疗组hs-CRP、IL-1β含量均显著下降(P<0.01);对照组hs-CRP、IL-1β含量均有下降趋势,但差异均无统计学意义(P>0.05);治疗组在改善hs-CRP、IL-1β含量方面均显著优于对照组(P<0.01)。【结论】对冠心病心绞痛患者,在常规西药治疗的基础上加用益气活血通络法治疗,能更好地达到缓解心绞痛、改善临床症状的目的,这可能与其改善血管内皮功能和免疫调节功能等有关。 相似文献
95.
96.
目的 探讨注射用益气复脉(冻干)联合多巴胺/多巴酚丁胺治疗心源性休克的临床疗效。方法 选取郑州市中医院2018年1月-2019年12月收治的心源性休克患者120例为研究对象,采用随机数字法最终分为对照组(54例)和观察组(52例)。对照组患者在常规治疗的基础上给予大剂量盐酸多巴胺注射液5~20 μg/(kg·min)和盐酸多巴酚丁胺注射液5~15 μg/(kg·min)治疗。观察组在对照组治疗基础上静滴注射用益气复脉(冻干)2.6~5.2 g/次,加入5%葡萄糖注射液或0.9%氯化钠注射液250~500 mL中,1次/d。疗程为7~14 d。观察两组患者的临床疗效和不良反应情况,同时比较两组治疗前后的血压和尿量水平。结果 治疗后,观察组患者总有效率为94.2%,显著高于对照组的81.5%,两组比较差异有统计学意义(P<0.05)。治疗后,两组血压和尿量水平均明显改善,同组治疗前后比较差异有统计学意义(P<0.05、0.01),观察组的血压和尿量水平显著高于对照组,两组比较差异有统计学意义(P<0.05、0.01)。两组不良反应发生率差异无统计学意义。结论 注射用益气复脉(冻干)联合多巴胺/多巴酚丁胺治疗心源性休克患者具有一定的临床疗效,能够显著改善血压和尿量水平。 相似文献
97.
目的 测定注射用益气复脉(冻干)(YQFM)冲管液安全剂量。方法 以YQFM为研究对象,以0.9%氯化钠注射液为稀释剂和冲管溶液,采用紫外-可见分光光度法测定冲管液中主药成分残留,确定冲管液的安全剂量;收集各段冲管液,在冲管液中加入常用配伍药物呋塞米注射液,采用紫外-可见分光光度法对冲管安全剂量进行验证;在冲管液中加入注射用环磷酰胺,采用不溶性微粒检查法对冲管液安全剂量进行验证。结果 YQFM 0.9%氯化钠溶液特征吸收波长为203和283 nm,浓度-吸收趋势拟合显示线性良好;在0~300 min内稳定性较好;冲管速度为40滴/min(2 mL/min)时,YQFM冲管液安全剂量为32.0 mL/min,经验证冲管效果符合要求。结论 为保证临床用药的安全性,建议YQFM冲管液用剂量应不少于32.0 mL。 相似文献
98.
99.
100.
Pharmacokinetics of different dosage of astragalus membranaceus of buyang huanwu decoction in rats with cerebral ischemic injury by microdialysis combined with LC/MS 下载免费PDF全文
Shengxin Wang Xiangli Yan Haozhen Zheng Jianye Yu Aiming Yu Xiao Shen Lisheng Wang 《中国药学》2020,29(2):90-101
To investigate the pharmacokinetics of effective components of Bu Yang Huang Wu Decoction (BYHWD) with different dosages of Astragalus (Yiqi groups and Huoxue groups ) applicating in rats with middle cerebral artery occlusion (MCAO). Replicating the animal model of cerebral ischemia-reperfusion in rats, establishing the liquid-mass spectrometry method for the determination of BYHWD and researching the pharmacokinetics of effective components of yiqi groups of BYHWD with different dosages of astragalus (3.09, 6.17, 12.34 g/Kg) and Huoxue goups (2.32 g/Kg) when applicated seperately in the rats suffering from cerebral ischemia reperfusion injury after femoral vein administration. The pharmacokinetics of formononetin and paeoniflorin in the different dosage groups of BYHWD met the one-compartment model, and the t1/2 of formononetin and paeoniflorin in the low-dose Yiqi and Huoxue groups were (88.43±3.82, 69.18±0.11) min, MRT were (138.56±4.83, 113.62±2.42) min, and AUC0–t were (28 488.35±4800.32, 140 614.80±23 954.05) ng/mL·min; The t1/2 of formononetin and paeoniflorin in the middle-dose Yiqi group and Huoxue group were (82.16±1.78, 67.08±3.69) min, and MRT were (127.95±2.70, 116.58±4.13), AUC0–t were (48 619.25±6745.75, 159 026.00±15 003.33) ng/mL·min; The t1/2 of formononetin and paeoniflorin in the high-dose Yiqi and Huoxue groups were (80.29±1.12, 69.69±0.87) min, and MRT was (128.79±1.46, 118.78±4.56) min, AUC0–t were (109 942.90±13 101.83, 189 417.90±22 311.00) ng/mL·min. The concentration rate of formononetin t1/2 brain was decreased with increase of Astragalus dose. However, no significant difference between these two variables was found during experiments. Furthermore, the experiments showed that the increasing dose of astragalus would affect the pharmacokinetic behavior of paeoniflorin in the Huoxue groups. More specifically, the result showed that paeoniflorin can be metabolized more slowly in the body when applicated in high dose of the jaundice administration groups . In this way, the effect of paeoniflorin can be lasted for longer time in the body and brain. 相似文献